Guideline registry — type 2 diabetes¶
Last curated: 2026-10-30. Last checked: 2026-10-30. New PubMed identifiers were retrieved through live E-utilities; current web-only documents were rechecked on their publisher sites.
Master table¶
| Body | Year | Region | Scope | Citation/URL | Status |
|---|---|---|---|---|---|
| ADA | 2026 | US/global | Full Standards of Care | Diagnosis PMID 41358893; pharmacology PMID 41358900; CV PMID 41358899; microvascular PMID 41358886 | current; annual |
| ADA/EASD | 2026 | US/Europe | Holistic T2D management and early organ protection | Davies et al., PMID 42825450 | current; supersedes 2022 |
| EASD | 2026 | International | Assessment and management of diabetes distress in adults with T1D or T2D | Speight et al., PMID 42744915 | current |
| Asia-Pacific Guideline Development Group | 2026 | Asia-Pacific (11 countries) | Injectable intensification after suboptimal GLP-1RA response | Luo et al., PMID 42543082 | current |
| EJHF (Heart Failure Association journal) expert consensus | 2026 | Europe | Pharmacological HF prevention across the cardiovascular-kidney-metabolic spectrum, including T2D | Inciardi et al., PMID 42817848 | current consensus statement (not a graded guideline) |
| Malaysian Expert Panel on DSPN | 2026 | Malaysia | Identification, evaluation and pharmacological management of sensorimotor polyneuropathy | Lim et al., PMID 42928304 | current regional expert consensus |
| EASL/EASD/EASO | 2026 | Europe/international | Resmetirom and semaglutide as MASH-targeted therapy; relevant to T2D comorbidity | PMID 42805503 | current focused guidance; detailed synthesis pending |
| ADA/EASD | 2022 | International | Hyperglycaemia/person-centred treatment | Davies et al., PMID 36148880 | superseded by 2026 |
| ACP | 2024 | US | Newer pharmacologic treatment | Qaseem et al., PMID 38639546; evidence review PMID 38639549 | current |
| AACE | 2022/2023 | US/global | Comprehensive diabetes care and T2D algorithm | Guideline PMID 35963508; algorithm PMID 37150579 | current |
| ESC | 2023 | Europe | Cardiovascular disease in diabetes | Marx et al., PMID 37622663 | current |
| NICE | 2026 | England/Wales | Adult T2D management | https://www.nice.org.uk/guidance/ng28 | current; updated 2026-02-18 |
| KDIGO | 2022; 2026 draft | International | Diabetes with CKD | https://kdigo.org/guidelines/diabetes-ckd/ | 2022 current; 2026 draft being revised after public review |
| IDF | 2025 | Global | Optimal and basic-care T2D strategies | https://idf.org/our-activities/education/idf-clinical-practice-recommendations-for-type-2-diabetes-2025/ | current |
| WHO | 2020 | Global/primary care | HEARTS-D diagnosis and management | https://www.who.int/publications/i/item/who-ucn-ncd-20.1/ | current technical module |
| WHO | 2018 | Global/resource-sensitive | Second/third-line glucose-lowering drugs and insulin | https://iris.who.int/bitstream/handle/10665/272433/9789241550284-eng.pdf | current but pre-organ-protection era; update needed |
| Diabetes Canada | 2024 | Canada | Pharmacologic glycaemic management | https://guidelines.diabetes.ca/cpg | current chapter |
| Diabetes Canada | current web chapter | Canada | Remission | https://guidelines.diabetes.ca/cpg/special-article-remission-of-type-2-diabetes | current |
| IDF | 2017 | Global/primary care | Primary-care T2D | https://idf.org/news-and-resources/resources/idf-clinical-practice-recommendations-for-managing-type-2-diabetes-in-primary-care/ | superseded by → IDF 2025 |
| NICE | 2015/2022 | England/Wales | Earlier NG28 iterations | NG28 update history | superseded within living NG28 → 2026 |
| ADA/EASD | earlier consensus cycles | International | Hyperglycaemia | recorded through 2022 report | superseded by → ADA/EASD 2022 → 2026 |
ADA Standards of Care 2026¶
- Annual, modular standard; relevant verified PubMed records: diagnosis/classification (PMID 41358893), pharmacologic approaches (PMID 41358900), cardiovascular risk (PMID 41358899), retinopathy/neuropathy/foot (PMID 41358886), and summary of revisions (PMID 41358896).
- Organ-protective treatment is selected by ASCVD, HF and CKD phenotype, not only HbA1c.
- Status: current; next scheduled annual cycle is the principal watch item.
ADA/EASD 2026 consensus¶
- The 2026 consensus broadens the prior hyperglycaemia focus to weight, cardiovascular and kidney risks, multiple long-term conditions, psychological support and access (Davies 2026, PMID 42825450).
- It favours earlier SGLT2 inhibitor or GLP-1-based therapy, potentially from diagnosis, and considers combination therapy for people with CVD, CKD or heart failure. Direct randomised evidence for incremental hard outcomes of the combination remains limited.
- Status: current; supersedes the 2022 consensus (Davies 2022, PMID 36148880).
EASD 2026 diabetes distress guideline¶
- Recommends routine discussion, validated assessment at least annually, and collaborative response to diabetes distress. For adults with T2D, psychological and educational interventions receive conditional recommendations; the certainty of evidence varies from very low to low (Speight 2026, PMID 42744915).
- Status: current; it complements the broad ADA/EASD treatment consensus rather than replacing it.
Asia-Pacific 2026 intensification beyond GLP-1RA¶
- GRADE guideline from a 22-member panel across 11 Asia-Pacific countries, built on eight RCTs (search updated November 2025). Conditionally recommends against switching to another GLP-1RA (very low certainty). Conditionally recommends switching to dual GIP/GLP-1RA (low certainty), switching to a fixed-ratio insulin/GLP-1RA combination (very low to moderate) or adding basal insulin with structured education (low) (Luo 2026, PMID 42543082).
- Status: current. It is a narrow decision guideline, and its evidence base is thin, as the certainty ratings show.
EJHF 2026 CKM heart-failure prevention consensus¶
- Recommends early, parallel initiation of RAS inhibitors, SGLT2 inhibitors, non-steroidal MRAs and incretin-based agents across at-risk and pre-HF stages, with structured monitoring and multidisciplinary pathways (Inciardi 2026, PMID 42817848).
- Status: an expert consensus statement, not a graded guideline. Its "parallel initiation" position runs ahead of the randomised combination evidence (see OQ-3).
ACP 2024 newer pharmacologic treatment¶
- Recommends adding an SGLT2 inhibitor or GLP-1 agonist to metformin and lifestyle when glycaemic control is inadequate; strong recommendation, high-certainty evidence (Qaseem 2024, PMID 38639546).
- Specifies outcome emphasis: SGLT2 inhibitors for mortality, MACE, CKD progression and HF hospitalisation; GLP-1 agonists for mortality, MACE and stroke.
- Recommends against adding a DPP-4 inhibitor to reduce morbidity or all-cause mortality.
- The supporting 84-RCT review found sparse direct comparisons and limited demographic/high-risk subgroup evidence; predefined minimally important differences were not met for several relative effects (Drake 2024, PMID 38639549).
- Status: current; tension with phenotype-first guidance is principally sequencing and metformin prerequisite, not disagreement that organ outcomes matter.
AACE 2022 guideline and 2023 algorithm¶
- The 2022 update contains 170 recommendations spanning diagnosis, targets, monitoring, obesity, vascular/kidney/eye/nerve disease, pharmacotherapy, hypoglycaemia, pregnancy, social determinants and virtual care (Blonde 2022, PMID 35963508).
- The 2023 algorithm presents both complication-centric and glucose-centric pathways, adds weight-loss medicines, and explicitly includes access/cost in clinical decisions (Samson 2023, PMID 37150579).
- Status: current. The algorithm's breadth means that not every branch rests on a direct randomised strategy comparison.
ESC 2023 cardiovascular disease in diabetes¶
- Organises diabetes treatment through cardiovascular risk and established disease, integrating glucose-lowering drugs with BP, lipid, antithrombotic and HF/CKD care (Marx 2023, PMID 37622663).
- Status: current European cardiovascular guidance; should be read with diabetes-specific and kidney guidance rather than as a complete glycaemic-care document.
ACP HbA1c target guidance (2018; still a live disagreement)¶
- Proposed HbA1c 7%–8% for most nonpregnant adults, consideration of deintensification below 6.5%, and symptom-focused treatment when life expectancy is <10 years because of advanced age or serious chronic illness (Qaseem 2018, PMID 29507945).
- ADA/AACE positions generally permit lower goals for healthy adults when achievable safely. The disagreement depends on how benefits, hypoglycaemia, burden and intervention type are weighted.
- Status: older than the 2024 ACP drug guideline but not superseded by it because scope differs; reappraisal watch.
NICE NG28 (2026 update)¶
- Last updated 18 February 2026 after medicine evidence review.
- For adults without relevant comorbidity, recommends modified-release metformin plus an SGLT2 inhibitor; if metformin is not tolerated/contraindicated, SGLT2 monotherapy.
- HbA1c targets distinguish regimens with and without hypoglycaemia risk and explicitly allow relaxation for frailty/comorbidity.
- Status: current living guideline.
KDIGO 2022 diabetes in CKD¶
- Layered care: lifestyle, renin–angiotensin-system blockade when indicated, SGLT2 inhibitor, statin, nonsteroidal mineralocorticoid receptor antagonist for selected albuminuria, and GLP-1RA when appropriate.
- FLOW (PMID 38785209) strengthens GLP-1RA kidney-outcome evidence after publication.
- Status reverified 2026-10-30: the 2022 guideline remains current and the 2026 draft is being revised after public review. Draft recommendations are not final guidance (KDIGO — “Diabetes and CKD”, https://kdigo.org/guidelines/diabetes-ckd/, accessed 2026-10-30).
IDF 2025¶
- Explicit “optimal” versus “basic care” strategies support use across unequal-resource systems.
- Covers glycaemia, weight, cardiorenal health, MASLD, technology and person-centred care.
- Supersedes IDF primary-care recommendations issued in 2017.
WHO guidance¶
- HEARTS-D 2020 consolidates diagnosis and management for primary-care systems and aligns with WHO-PEN.
- WHO 2018 second/third-line guidance prioritised sulfonylurea after metformin and human insulin on cost/resource grounds; it predates much of the organ-outcome evidence and is a major temporal disagreement with ADA/NICE/IDF.
Diabetes Canada¶
- Pharmacologic chapter updated 2024; broader guideline suite includes 2023 mental-health and hypoglycaemia updates.
- Remission chapter distinguishes remission to prediabetes (A1c 6.0–6.4%) and normal glucose (<6.0%), differing from the international consensus single <6.5% threshold (Riddle 2021, PMID 34462270).
Disagreements and gaps¶
| Issue | Positions | Evidence gap |
|---|---|---|
| Initial therapy without comorbidity | NICE 2026: metformin+SGLT2; other systems allow staged/alternative starts | Direct pragmatic outcome/cost comparison |
| Metformin prerequisite | ACP 2024 frames SGLT2/GLP-1 addition to metformin; ADA/EASD permits organ-protective use independent of metformin in relevant disease | Strategy trial across baseline risk and resource settings |
| Default HbA1c | ACP 2018: 7%–8% for most; ADA/AACE often lower for healthy adults when safe | Guideline-strategy comparison by age, frailty and drug hypoglycaemia risk |
| DPP-4 role | ACP recommends against addition for morbidity/mortality reduction; other algorithms retain it for glycaemic tolerability | Patient-important comparative effectiveness where organ benefit is not primary |
| Resource-constrained second line | WHO 2018 prioritises sulfonylurea; modern guidance prioritises organ outcomes | Contemporary LMIC cost-effectiveness and access |
| Remission threshold | International consensus <6.5%; Diabetes Canada splits prediabetes/normal ranges | Which definition predicts complications |
| SGLT2+GLP-1 combination | Increasingly layered | Direct hard-outcome incremental RCT evidence |
| Weight as co-primary goal | Stronger in ADA/EASD/IDF | Long-term patient-defined and functional outcomes |
| Youth extrapolation | Adult evidence often extrapolated | Paediatric cardiorenal outcome trials |
October 2026 verification¶
- ADA’s official Standards page still points to the 2026 edition (https://professional.diabetes.org/standards-of-care, accessed 2026-10-30); NICE NG28 still lists 18 February 2026 as its latest update (https://www.nice.org.uk/guidance/ng28, accessed 2026-10-30).
- A correction to the parallel Diabetologia ADA/EASD report changes the ESSENCE interim-analysis sample size from 320 to 800, without changing conclusions (Davies 2026, PMID 42955083).
- The Malaysian DSPN consensus was read in full. Its emphasis is sensory examination even without pain and locally feasible testing (Lim 2026, PMID 42928304).
- The EASL/EASD/EASO MASH guidance was verified in PubMed and Crossref. Search-rendered publisher text was available, but direct full-text opening returned 403; detailed recommendation extraction is deferred (PMID 42805503).
Watch list¶
- ADA Standards 2027 publication.
- ADA/EASD 2026 implementation material and corrections.
- ACP HbA1c target guidance reappraisal in the organ-protection/low-hypoglycaemia era.
- AACE algorithm update incorporating SOUL and active-comparator SURPASS-CVOT results.
- ESC cardiovascular guidance update after FLOW/SOUL/SURPASS-CVOT.
- WHO pharmacologic update incorporating SGLT2/GLP-1 organ outcomes and generic pricing.
- KDIGO 2026 draft finalisation and any changes after public review (draft status reverified 2026-10-30).
- Cochrane review "Blood pressure targets for hypertension in people with diabetes mellitus": a protocol only, published 2026-09 (Larvie 2026, PMID 42788405). Watch for the completed review; it would bear on the BP-target sections of ADA, ESC and KDIGO.
- NICE technology/appraisal changes for tirzepatide and higher-dose semaglutide.
- IDF corrections or regional implementation supplements to 2025 recommendations.